ARQ 092

Drug Profile

ARQ 092

Alternative Names: ARQ-092

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator ArQule; Daiichi Sankyo Company
  • Developer ArQule; National Human Genome Research Institute
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Proteus syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Proteus syndrome; Solid tumours
  • Preclinical Brain disorders; Congenital heart defects; Sickle cell anaemia

Most Recent Events

  • 08 Mar 2017 The EMA approves IND application for ARQ 092 in PIK3CA-related overgrowth spectrum family of rare diseases, including Proteus syndrome
  • 03 Dec 2016 Pharmacodynamics data from preclinical trials in Sickle cell anaemia presented at the Annual Meeting of the American Society of Hematology (ASH-2016)
  • 12 Nov 2016 Preclinical trials in Congenital heart disorders in USA before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top